Keywords
Incidence
Mortality
Submitted : 2024-04-21
Accepted : 2024-05-06
Published : 2024-05-21
Abstract
In this paper, the literature on the incidence and death of malignant tumors in the Chongqing and Jiangsu provinces from 2014–2016 was collected through a literature review. The overall incidence, mortality, tumor spectrum, and possible risk factors of malignant tumor incidence and death in the Chongqing and Jiangsu provinces were compared and analyzed. This aims to provide references and suggestions for the prevention and control of malignant tumors in China.
References
Chen W, Sun K, Zheng R, et al., 2018, Cancer Incidence and Mortality in China, 2014. Chinese Journal of Cancer Research, 30(1): 1–12.
Zhang S, Sun K, Zheng R, et al., 2020, Cancer Incidence and Mortality in China, 2015. Chinese Journal of Cancer Research, 1(1): 2–11.
Zheng RS, Zhang S, Sun KX, et al. 2023, Prevalence of malignant tumors in China in 2016. Chinese Journal of Cancer Research, 45(3): 212–220.
Zhang W, Qiu H, Ding X, et al., 2017, Study on the Epidemiological Data and Prevention and Treatment of Malignant Tumors in Chongqing in 2014. Chongqing Medical Journal, 46(11): 1511–1515.
Ding X, Lu X, et al., 2017, Incidence and Mortality of Malignant Tumors in Chongqing in 2015. China Prevention and Control of Chronic Diseases, 25(1): 73–77.
Ding XB, Tang WG, Zeng YS, et al., 2019, Analysis of Disease Burden of Malignant Tumors in Chongqing in 2016. Chinese Journal of Chronic Disease Prevention and Control, 27(8): 580–584.
Han RQ, Wu M, Luo PF, et al., 2018, Incidence and Death of Malignant Tumors in Jiangsu Province in 2014. Cancer Prevention and Treatment, 31(1): 24–31.
Han RQ, Wu M, Miao WG, et al., 2019, Incidence and Death of Malignant Tumors in Jiangsu Province in 2015. Chinese Oncology, 29(2): 81–89.
Han RQ, Wu M, Miao WG, et al., 2019, Prevalence of Malignant Tumors in Jiangsu Province in 2016. Journal of Practical Oncology, 34(4): 291–297.
Huo Y, Guo Z, 2019, Progress of Clinical Application of Autoantibodies to Lung Cancer in Early Diagnosis and Treatment of Tumor. Marker Immuno-Analysis and Clinic, 26(5): 5.
Wender R, Fontham ET, Barrera ETR, et al., 2013, American Cancer Society Lung Cancer Screening Guidelines. CA Cancer J Clin, 63(2): 107–117.
National Lung Screening Trial Research Team, Alerle DR, Adams AM, et al., 2011, Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med, 365(5): 395–409.
Qiu GL, 2021, Cause Analysis and Nursing Countermeasures of Hepatitis B Vaccine Non-Compliance in Neonates. Science and Health, 24(4): 77.
Hu Y, Lei F, 2022, Analysis and Prediction of Malignant Tumor Trend in China Based on Grey Model. Corps Medicine, 2022(2): 15–18.
Sun Y, Huang X, 2021, Problems to be Solved and Countermeasures in The Treatment of Hematologic Tumors in China. Chinese Journal of Internal Medicine, 60(10): 3.